(Total Views: 754)
Posted On: 07/05/2024 9:42:21 AM
Post# of 154094
There is a new article in the journal "Science Translational Medicine" entitled
PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections
https://www.science.org/doi/10.1126/scitranslmed.adi6887
Here is an excerpt:
Ohm, your regulator list shows that LL downregulates PI3K. Is there any new information in the article that would be applicable to LL, e.g., possible additions to your disease list?
PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections
https://www.science.org/doi/10.1126/scitranslmed.adi6887
Here is an excerpt:
Quote:
PI3Kγ inhibition promoted survival across distinct mouse models of respiratory inflammation and reduced inflammation and vascular leak in the lungs of these animals. These data, which span across human and murine studies, suggest that PI3Kγ inhibition may be an effective host-directed therapy for lung inflammation.
Ohm, your regulator list shows that LL downregulates PI3K. Is there any new information in the article that would be applicable to LL, e.g., possible additions to your disease list?
(9)
(0)
